HC Wainwright Issues Negative Estimate for Agenus Earnings

Agenus Inc. (NASDAQ:AGEN) – Equities research analysts at HC Wainwright lowered their Q1 2026 earnings per share (EPS) estimates for shares of Agenus in a research note issued to investors on Monday, March 16th. HC Wainwright analyst E. Bodnar now anticipates that the biotechnology company will post earnings of $1.45 per share for the quarter, down from their previous forecast of $1.49. The consensus estimate for Agenus’ current full-year earnings is ($12.55) per share. HC Wainwright also issued estimates for Agenus’ Q2 2026 earnings at ($0.56) EPS, Q3 2026 earnings at ($0.18) EPS, Q4 2026 earnings at ($0.21) EPS and FY2026 earnings at $0.41 EPS.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Agenus in a research report on Monday, December 29th. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $14.50.

Agenus Stock Up 1.3%

Shares of NASDAQ AGEN opened at $3.81 on Wednesday. The stock has a market cap of $146.30 million, a P/E ratio of -8.28 and a beta of 1.57. The firm’s 50-day simple moving average is $3.27 and its 200 day simple moving average is $3.77. Agenus has a fifty-two week low of $1.38 and a fifty-two week high of $7.34.

Agenus (NASDAQ:AGEN) last released its quarterly earnings results on Monday, March 16th. The biotechnology company reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.27) by $1.83. The company had revenue of $34.20 million during the quarter, compared to analysts’ expectations of $28.10 million. Agenus had a negative return on equity of 7.65% and a negative net margin of 2.67%.

Institutional Investors Weigh In On Agenus

A number of institutional investors and hedge funds have recently modified their holdings of AGEN. Bank of Montreal Can purchased a new stake in shares of Agenus during the second quarter valued at $75,000. Savant Capital LLC acquired a new stake in Agenus during the 2nd quarter worth about $73,000. Walleye Capital LLC acquired a new stake in Agenus during the 2nd quarter worth about $906,000. XTX Topco Ltd acquired a new stake in Agenus during the 2nd quarter worth about $272,000. Finally, Catalyst Funds Management Pty Ltd purchased a new stake in Agenus during the second quarter valued at about $50,000. Institutional investors and hedge funds own 61.46% of the company’s stock.

About Agenus

Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.